Platinum and Palladium-triazole Complexes as Highly Potential Antitumor Agents

✍ Scribed by Najim A. Al-Masoudi; Bayazeed H. Abdullah; Ali H. Essa; Roberta Loddo; Paolo LaColla

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 765 KB
• Volume: 343
• Category: Article
• ISSN: 0365-6233
• DOI: 10.1002/ardp.200900140

✦ Synopsis

The palladium complexes [(dppe)Pd(L) 2 PdCl 2 ], [(dppe)Pd(L) 2 PtCl 2 ], [(dppp)Pd(L) 2 PdCl 2 ], [(dppm) Pd(L) 2 NiCl 2 ], and [(dppm)Pd(L) 2 SnCl 4 ] 15 -19 were prepared. The antiproliferative activity of the newly synthesized complexes as well as their previously prepared analogues 3 -14 and 20 -26 were screened against a large panel of human cancer cell lines derived from haematological CD4 + human T-cells containing an integrated HTLV-1 genome (MT-4). The complex 12a, b exhibited remarkable antiproliferative activity against MT-4, CD4 + human acute T-lymphoblastic leukemia (CCRF-CEM), human splenic B-lymphoblastoid cells (WIL-2NS), human acute B-lymphoblastic leukemia (CCRF-SB), skin melanoma (SK-MEL-28), and prostate carcinoma (DU145) cell lines (CC 50 = 0.5 lM, 0.4 € 0.05 lM, 0.6 € 0.05 lM, 0.4 € 0.1 lM, and 0.8 € 0.2 lM, respectively), meanwhile, 9a, b, 14a, b, and 23 showed significant activity against the CCRF-SB cell lines (CC 50 = 0.6 € 0.06 lM, 0.7 € 0.05 lM, 0.6 € 0.05 lM, and 0.8 € 0.15 lM, respectively). Further, 19 exhibited activity against the CCRF-CEM cell line (CC 50 = 0.4 € 0.05 lM).